Semaglutide
Also known as: Ozempic · Wegovy · Rybelsus
Contents
MW
4113.58 Da
Amino Acids
31 AA
Half-Life
7 days
Route
SubQ, Oral
CAS
910463-68-2
Formula
C187H291N45O59
Mechanism of Action
Semaglutide is a long-acting synthetic GLP-1 receptor agonist sharing 94% sequence homology with native GLP-1. Two modifications: C18 fatty acid chain at lysine-26 (albumin binding, extending half-life from 2 min to 7 days) and Ala→AIB substitution at position 8 (DPP-IV resistance).
MECHANISM 1 — PANCREATIC β-CELL: Binds GLP-1R → adenylyl cyclase → cAMP → PKA/EPAC2 → glucose-dependent insulin secretion. CRITICAL: Insulin release is glucose-dependent — hypoglycemia is rare in non-diabetics.
MECHANISM 2 — GLUCAGON SUPPRESSION: GLP-1R on α-cells → suppresses glucagon → reduces hepatic glucose output.
MECHANISM 3 — CENTRAL APPETITE SUPPRESSION: GLP-1R expressed in hypothalamic arcuate nucleus, area postrema, NTS. Semaglutide crosses BBB → reduces caloric intake by 20–30%.
MECHANISM 4 — GASTRIC EMPTYING DELAY: Slows gastric emptying → reduced post-meal glucose + extended satiety. Also causes nausea (especially early).
MECHANISM 5 — CARDIOVASCULAR: SELECT trial (N=17,604) — 20% MACE reduction via reduced arterial inflammation, improved endothelial function, reduced LDL/triglycerides, decreased plaque progression.
Dosing Protocol
Low Dose
███ – ███ mcg/day
Standard Dose
███ mcg/day
High Dose
███ – ███ mcg/day
Dosing protocols are for paid members
Get exact dosing ranges, injection frequency, timing rationale, and reconstitution math.
Get Clinical Access — $79/moFrequency
Once weekly, same day each week.
Half-Life
7 days
Reconstitution Guide
Full reconstitution protocol with BAC water volumes, concentration math, and units-to-draw per dose is available on the Clinical plan.
Unlock reconstitution guide →Clinical Warnings
FDA BOXED WARNING: Thyroid C-cell tumors in rodents. Contraindicated with MTC/MEN2 history.
Pancreatitis: discontinue immediately if suspected.
Diabetic retinopathy complications with rapid HbA1c improvement.
Acute kidney injury from dehydration (GI side effects).
Gallbladder disease increased.
Muscle loss — resistance training + high protein (1.6–2.4 g/kg/day) essential.
Compounding quality warnings from FDA.
Discontinuation rebound: 2/3 weight regain within 1 year.
Contraindications
Absolute
Personal or family history of medullary thyroid cancer
MEN2 syndrome
Pregnancy
Pancreatitis
Relative Cautions
Type 1 diabetes
Gastroparesis
Diabetic retinopathy
Gallbladder disease
Side Effect Profile
Mild
- ●Nausea
- ●Diarrhea
- ●Constipation
Moderate
- ●Vomiting
- ●Abdominal pain
- ●Headache
- ●Fatigue
Severe (Rare)
- ●Pancreatitis
- ●Thyroid C-cell tumors (boxed warning)
- ●Acute kidney injury
Synergistic Peptides
Common Stacks
Tirzepatide
Retatrutide
Research Status
GOLD STANDARD — EXTENSIVE PHASE III DATA. FDA-APPROVED. STEP 1 (PMID 33567185): N=1,961, 14.9% weight loss at 68 weeks. SELECT (PMID 38149595): N=17,604, 20% MACE reduction. SUSTAIN-6 (PMID 27633186): N=3,297, CV safety in T2D. FDA-approved: Ozempic (T2D), Wegovy (obesity), Rybelsus (oral T2D).
Frequently Asked Questions
How does Semaglutide work?
Semaglutide is a long-acting synthetic GLP-1 receptor agonist sharing 94% sequence homology with native GLP-1. Two modifications: C18 fatty acid chain at lysine-26 (albumin binding, extending half-life from 2 min to 7 days) and Ala→AIB substitution at position 8 (DPP-IV resistance). MECHANISM 1 — PANCREATIC β-CELL: Binds GLP-1R → adenylyl cyclase → cAMP → PKA/EPAC2 → glucose-dependent insulin secretion. CRITICAL: Insulin release is glucose-dependent — hypoglycemia is rare in non-diabetics. MEC
What is the standard dose of Semaglutide?
Semaglutide dosing protocols are available with a ClinPep Clinical subscription. Dosing varies by indication and patient factors — consult a licensed healthcare provider. General frequency: Once weekly, same day each week.
What is the half-life of Semaglutide?
The half-life of Semaglutide is 7 days. This determines optimal dosing frequency and timing.
Who should not use Semaglutide?
Semaglutide is absolutely contraindicated in: Personal or family history of medullary thyroid cancer; MEN2 syndrome; Pregnancy; Pancreatitis. Use with caution in: Type 1 diabetes; Gastroparesis; Diabetic retinopathy.
What are the side effects of Semaglutide?
Common mild side effects include: Nausea, Diarrhea, Constipation. Moderate effects: Vomiting, Abdominal pain, Headache, Fatigue.
What peptides stack well with Semaglutide?
Semaglutide is commonly stacked with: Tirzepatide, Retatrutide, AOD-9604.
How do you reconstitute Semaglutide?
Semaglutide is reconstituted with bacteriostatic water. Exact volumes, concentrations, and units-to-draw calculations are available in the ClinPep Clinical plan. Always follow your compounding pharmacy's instructions.
How long should you cycle Semaglutide?
Semaglutide cycle protocols vary by indication. Detailed cycle length, on/off schedules, and monitoring guidelines are available with ClinPep Clinical access. Consult your healthcare provider for personalized cycling guidance.
References & Citations
10 PubMed studies · 3 clinical trials
Semaglutide-induced transient intestinal ischemia: A case report.
Kalluru Pavan Kumar Reddy, Cherukuri Apoorva, Kuchi Deekshitha, Topacio Antonia. International journal of clinical pharmacology and therapeutics. 2026
Obesity is a global health issue that impacts millions of people worldwide. Semaglutide is a glucagon-like peptide-1 receptor agonist that was initially developed as a treatment for type 2 diabetes me
The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials.
Pilśniak Joanna, Węgrzynek-Gallina Julia, Bednarczyk Błażej, Buczek Aleksandra et al.. Life (Basel, Switzerland). 2025
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes and obesity due to their metabolic effects. Emerging evidence suggests they may also have neuro
Metformin-Enhanced Digital Therapeutics for the Affordable Primary Prevention of Diabetes and Cardiovascular Diseases: Advancing Low-Cost Solutions for Lifestyle-Related Chronic Disorders.
Farley Brian, Radetich Emi, DAlessandro Joseph, Bulaj Grzegorz. Healthcare (Basel, Switzerland). 2025
Each year, over 1 million people in the United States die from diabetes and cardiovascular diseases (CVDs). These largely preventable chronic conditions also create a financial burden on patients, pay
GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects.
Barać Milena, Roganović Jelena. Biology. 2025
This review addresses the growing concern of oral side effects, particularly dry mouth, associated with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) widely used for diabetes and o
Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.
Myers Walter K, Heath Garrett, Rohrer Bärbel. Ophthalmology. Retina. 2025
To compare the hazard of age-related macular degeneration (AMD) among nondiabetic, weight loss-eligible adults prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide or liragluti
Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity.
Ferrulli Anna, Senesi Pamela, Sonaglioni Andrea, Cannavaro Daniele et al.. Obesity (Silver Spring, Md.). 2026
This study compared the efficacy of a GLP-1 receptor agonist (GLP1-RA) (semaglutide, 0.5 mg/week), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and repetitive transcranial magnetic
Effectiveness of GLP-1 RAs and SGLT2 inhibitors in preventing T2DM in high-risk patients: an updated systematic review and meta-analysis.
Tsironikos Georgios I, Tsolaki Vasiliki, Zakynthinos George E, Kyprianidou Despoina et al.. Frontiers in clinical diabetes and healthcare. 2025
There are conflicting results and limited data regarding the individual effectiveness of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors and
Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols.
Davila Diaz Rodrigo, Campos Barrera Eugenia, Diaz Fosado Luis Alfonso, Reyes Esparza Arturo et al.. Cureus. 2025
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed among plastic surgery patients for obesity and overweight. Agents such as dulaglutide, liraglutide, semaglutide, and t
Registered Clinical Trials
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
Gastric Emptying in Healthy Volunteers and GLP-1 Agonist Users
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
Symptom Indications
Full Clinical Access
Complete Semaglutide Protocol
Access reconstitution math, cycle guides, drug interaction checker, stack builder with contraindication analysis, symptom checker, and downloadable PDF handouts.
Secure payment powered by Stripe.
This information is for educational and research reference purposes only. ClinPep does not provide medical advice, diagnosis, or treatment recommendations. All protocols should be reviewed by a licensed healthcare provider.